Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Escalating Dose R21/Matrix-M™ in Healthy Adults
NCT06320535Phase 1Completed
- Sponsor
- University of Oxford
- Start
- Mar 2024
- Primary completion
- Sep 2026
- Modality
- Recombinant Protein Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label trial of R21/Matrix-M in malaria (3 arms), sponsored by University of Oxford. Primary endpoints: Number of solicited adverse events, Number of unsolicited adverse events and laboratory adverse events and 2 more. Started Mar 2024; status: completed.
02
Drugs
R21/Matrix-M
03
Conditions
malaria
Beyond the preview
Go deeper on NCT06320535.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06320535.